<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734758</url>
  </required_header>
  <id_info>
    <org_study_id>248994</org_study_id>
    <nct_id>NCT02734758</nct_id>
  </id_info>
  <brief_title>Markers of Atrial Fibrillation</brief_title>
  <official_title>Atrial Fibrillation in Ischemic Stroke: Strengthening Identification and Decisions to Anticoagulate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <brief_summary>
    <textblock>
      This study will evaluate whether a gene marker can improve the identification of atrial&#xD;
      fibrillation in patients with ischemic stroke, and evaluate whether the decision to&#xD;
      anticoagulate could be improved by a marker of atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation (AF) is a major cause of ischemic stroke that is critical to identify&#xD;
      because anticoagulation provides a 66% risk reduction in recurrent stroke. However,&#xD;
      opportunities to prevent stroke due to AF are frequently missed because AF is paroxysmal and&#xD;
      therefore not detected at the time of stroke. In addition, even when AF is identified&#xD;
      anticoagulation may not be initiated due to perceived contraindications.&#xD;
&#xD;
      This study will (1) evaluate whether a gene marker can improve the identification of AF in&#xD;
      patients with ischemic stroke, and (2) evaluate decisions by health care provider and&#xD;
      patients to anticoagulate AF, and whether this decision could be improved by a marker of AF&#xD;
      at time of stroke. An AF Gene Score will be developed comprised of genes associated with&#xD;
      inflammatory and thrombotic pathways related to risk of AF thromboembolism in stroke patients&#xD;
      with AF. The AF Gene Score measured at time of stroke can stroke will permits rapid&#xD;
      identification of stroke due to AF which may increase initiation of anticoagulation therapy.&#xD;
      This is important in cryptogenic stroke, where prolonged monitoring leaves uncertainty&#xD;
      regarding the association of delayed AF with initial stroke and delays anticoagulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2011</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression</measure>
    <time_frame>Post stroke through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">131</enrollment>
  <condition>Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Atrial fibrillation stroke</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-atrial fibrillation Stroke</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ischemic stroke&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ischemic stroke within 72 hours of onset&#xD;
&#xD;
          -  Complete evaluation to determine cause of stroke&#xD;
&#xD;
          -  Informed Consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active Infection&#xD;
&#xD;
          -  Lymphoma / Leukemia / Blood dyscrasia&#xD;
&#xD;
          -  Hemorrhagic stroke&#xD;
&#xD;
          -  Immunosuppressive therapy&#xD;
&#xD;
          -  Illicit drug use&#xD;
&#xD;
          -  Blood transfusion +/- 1 month&#xD;
&#xD;
          -  Major surgery/trauma in last 6mts&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

